Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
June 17, 2019
RegMed Investors’ (RMi) pre-open: there are cracks in the downside glass
June 15, 2019
RegMed Investors’ (RMi) closing bell: alchemy in reverse
June 11, 2019
RegMed Investors’ (RMi) closing bell: risk has never stopped being a four letter expletive
May 31, 2019
RegMed Investors’ (RMi) closing bell: it’s good that May is over, RIP
May 30, 2019
RegMed Investors’ (RMi) pre-open: the sector suffers in silence
May 29, 2019
RegMed Investors’ (RMi) closing bell: sector uncertainty and markets pressured investors to dump equities
May 22, 2019
RegMed Investors’ (RMi) closing bell: sector digs itself deeper into being oversold
May 22, 2019
RegMed Investors’ (RMi) pre-open: what are the odds for the session?
May 21, 2019
RegMed Investors’ (RMi) closing bell: the oversold were recognized although volume was weak and breathe thin
May 21, 2019
RegMed Investors’ (RMi) pre-open: Beyond trade relief headlines, where is sector news?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.